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Panel Members
• Wayne Clough, chair, Georgia Tech
• M. Kathleen Behrens, R.S. Investments
• Erich Bloch, The Washington Advisory Group
• Raul J. Fernandez, Dimension Data
• Martha Gilliland, University of Missouri-Kansas City
• Walter E. Massey, Morehouse College
• Gordon E. Moore, Intel
• Luis M. Proenza, University of Akron
• George Scalise, Semiconductor Industry Association
• Charles M. Vest, MIT
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Assigned Tasks
• Review the federal R&D portfolio to 
determine which programs should be 
expanded, which curtailed, and which 
maintained at the same level.
• Advise on technology transfer mechanisms 
to maximize the commercialization and 
benefit of federally funded research.
Panel Workplan
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Schedule for Accomplishing Tasks
• July: Develop preliminary position on the 
Bayh-Dole Act and its benefits
• August: First assessment of federal 
investment in R&D and its national benefit 
relative to FY ‘04 budget
• October: Review of mechanisms for 
technology transfer/commercialization, 
including Bayh-Dole
• November: Final review of federal 
investment in R&D and its national benefit
Panel Workplan
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Data Collection Methods
• Two RAND studies being developed:
– Technology transfer
– Portfolio of federal R&D investments
• Organizations providing expertise to RAND:
– American Association for the Advancement of 
Science
– Association of University Technology Managers
• Hearings to solicit input from industry, 
universities, federal agencies, and others
Panel Workplan
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Experts Engaged
• David Mowery, UC Berkeley
• Marsha McNutt, Monterey Bay 
Aquarium Research Institute
• Jerry Thursby, Emory University
• Marie Thursby, Georgia Tech
• Jilda Garton, Georgia Tech
Panel Workplan
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Activities to Date
• February 18: Conference call
• March 5: First meeting, 8:30-10 am before 
full PCAST meeting
• April 11: Hearing on Bayh-Dole, afternoon
– Pharmaceutical Research and Manufacturers of 
America (PhRMA)
– Biotechnology Industry Association (BIO)
– Semiconductor Research Corporation (SRC)
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Activities to Date (cont)
• May 9: Hearing on Bayh-Dole, morning
– Association of University Technology Managers
– U.S. Department of Commerce
– Battelle Memorial Institute
– NIH Technology Transfer Office
• May 9: Hearing on technology transfer, afternoon
– IBM
– American Chemical Society
– Science Coalition
– Council on Competitiveness
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Activities to Date (cont)
• May 20: Conference call on Bayh-Dole
• June 13: Briefings on research activities of 
federal agencies:
– U.S. Department of Defense
– U.S. Department of Energy
– National Science Foundation
– National Aeronautic and Space Administration
– U.S. Department of Commerce
– U.S. Office of Management and Budget
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Status Report on RAND Study 
on Technology Transfer
Luis Proenza
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Status Report on RAND Study 
on Federal Investment in R&D
Erich Bloch
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The Bayh-Dole Act
The most pertinent question to ask is:
In whose hands will the vestiture of primary 
rights to inventions serve to transfer the 
inventive technology most quickly to the 
public for its use and benefit?
In the United States, the answer has been the 
university-private sector partnership.
Howard W. Bremer
to NASULGC, Nov 11, 2001
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Academic Patents Granted
National Science Board: Science & Engineering Indicators 2000
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University Licensing, FY 2000
• 3,764 U.S. patents issued
• 4,362 new licenses and options executed
• 66% of the new licenses to small 
businesses or start-up companies
• Over 450 new companies created to 
commercialize university research
• At least 347 new products introduced to 
the market
AUTM FY 2000 Survey
190 institutions reporting
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Licensing Revenues, FY 2000
• $29.5 billion in research expenditures 
• $1.26 billion* in adjusted gross income 
• Half earned less than $1 million
• 9% earned more than $20 million
AUTM FY2000 Survey
* Expected to be higher than the trendline because of one-
time payments (cash equity, patent-infringement suits, etc.).
190 institutions reporting
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Less than 1% of active licenses generate more 
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Insights from the Hearings
Bayh-Dole works!  If it is not broken, don’t fix it.
Jon Soderstrom, Yale (AUTM)
I have not yet heard an industry representative 
single out Bayh-Dole as a specific problem.
Bruce Mehlman, Dept of Commerce
Any major change in the law may cause a reaction 
in the commercial community that could impede 
what is now a positive flow of new therapeutic 
products and procedures to market.
Mark Rohrbaugh, NIH
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Insights from the Hearings
The Bayh-Dole Act has been a very positive tool 
in commercialization… It establishes ownership 
of IP with universities and they are motivated to 
work with industry to commercialize.  The 
Bayh-Dole Act requires them to do it, and over 
time they have become very good at it.
David Beier, PhRMA
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Insights from the Hearings
The success of Bayh-Dole has caused other 
issues to emerge:
– Conflicts of interest
– Recoupment
– Exclusive vs non-exclusive licenses; 
development and use of research tools
– Uneven implementation
– Projects that involve multiple collaborations 
and significant private investment
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Panel to Gather More Data




• Results from the RAND studies
